Connect with us

Health

Johnson & Johnson COVID-19 vaccine generates immune response in trial – New York Post

Johnson & Johnson’s coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.

Published

on

post featured image
ADVERTISEMENT

Johnson & Johnson’s coronavirus vaccine generated a lasting immune response to the deadly bug in an early-stage clinical trial, the pharmaceutical giant said.
More than 90 percent of the study’s 805 participants had neutralizing antibodies offering protection against COVID-19 29 days after receiving a single dose of the vaccine, the New Jersey-based drugmaker said Wednesday.
The antibodies stuck around for at least 71 days among the participants ranging in age from 18 to 55 years old, according…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
Pa. State Troopers Association criticizes state’s plan to vaccinate smokers before first responders – WGAL Susquehanna Valley Pa.
post featured image
Oregon reports 22 more COVID-19 deaths, 877 new cases, 16K more vaccinations – KTVZ
post featured image
Allegheny County Health Dept. to start vaccinating people 65 and older at its Monroeville clinic – WTAE Pittsburgh